Health
Commercialization of regenerative-medicine therapies | Nature Reviews Bioengineering
Oberweis, C. V., Marchal, J. A., López-Ruiz, E. & Gálvez-Martín, P. A worldwide overview of regulatory frameworks for tissue-based products. Tissue Eng. B 26, 181–196 (2020).
Jacques, E. & Suuronen, E. J. The progression of regenerative medicine and its impact on therapy translation. Clin. Transl. Sci. 13, 440–450 (2020).
Goula, A. et al. Advanced therapy medicinal products challenges and perspectives in regenerative medicine. J. Clin. Med. Res. 12, 780–786 (2020).
Sipp, D. & Okano, H. Japan strengthens regenerative medicine oversight. Cell Stem Cell 22, 153–156 (2018).
Kim, D.-S. & Bae, S. Impact and challenges of enactment for advanced regenerative medicine in South Korea. Front. Bioeng. Biotechnol. 10, 972865 (2022).
Qiu, T., Hanna, E., Dabbous, M., Borislav, B. & Toumi, M. Regenerative medicine regulatory policies: a systematic review and international comparison. Health Policy 124, 701–713 (2020).
Hogle, L. F. & Das, A. The social production of evidence: regenerative medicine and the 21st Century Cures Act. Regen. Med. 12, 581–586 (2017).
Brown, D. G. & Wobst, H. J. A decade of FDA-approved drugs (2010–2019): trends and future directions. J. Med. Chem. 64, 2312–2338 (2021).
Butler, D. Translational research: crossing the valley of death. Nature 453, 840–842 (2008).
Frederickson, R. M. Escaping the valley of death. Mol. Ther. 20, 476–478 (2012).
Hinsenkamp, A., Benyó, Z. & Hornyák, I. Overview of tissue engineering patent strategies and patents from 2010 to 2020, including outcomes. Tissue Eng. B 28, 626–632 (2022).
Allen-Hoffmann, L., Comer, A., Conrad, P. B., Hoffmann, M. & Ivarie, C. A.-R. Improved skin substitutes and uses thereof. Australian patent application 214639 B2 (2010).
Asano, S., Nakanishi, Y. & Sugiyama, D. Intellectual property in the field of regenerative medicine in Japan. Clin. Ther. 40, 1823–1827 (2018).
Pirnstill, J. & Allen-Hoffmann, B. L. Cold storage of organotypically cultured skin equivalents for clinical applications. US patent 10743533 B2 (2022).
Allen-Hoffmann, B. L., Pirnstill, J. C., Gratz, K. R. & Comer, A. R. Cryopreservation of viable human skin substitutes. Australian patent 232795 B2 (2019).
Koepsel, J. & Gratz, K. Tissue container systems. US patent application 0330542 A1 (2022).
Smiell, J., Comer, A., Lokuta, M. & Allen-Hoffmann, B. L. Methods for treating acute wounds and improving outcomes. Australian patent application 353695 A1 (2020).
Wang, S.-J. Patent portfolios for biotech inventions. Nat. Biotechnol. 31, 501–503 (2013).
Rachinsky, T. First-to-invent versus first-to-file: impact of the AIA. Pharm. Pat. Anal. 3, 353–359 (2014).
Begley, C. G. & Ioannidis, J. P. A. Reproducibility in science. Circ. Res. 116, 116–126 (2015).
Ozyhar, T., Barnabei, L. & Myrick, D. When speed matters: a discussion on the benefits of a grace period in patent law to accelerate pharmaceutical innovation in times of pandemic. J. Law Biosci. 9, lsac004 (2022).
Sherkow, J. S. Preprint servers and patent prior art. EMBO Rep. 23, e54439 (2022).
Armstrong, J. P. K. et al. A blueprint for translational regenerative medicine. Sci. Transl. Med. 12, eaaz2253 (2020).
Crama, P., Reyck, B. D. & Degraeve, Z. Milestone payments or royalties? Contract design for R&D licensing. Oper. Res. 56, 1539–1552 (2008).
Nordberg, R. C., Otarola, G. A., Wang, D., Hu, J. C. & Athanasiou, K. A. Navigating regulatory pathways for translation of biologic cartilage repair products. Sci. Transl. Med. 14, eabp8163 (2022).
Zscharnack, M. et al. Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP). J. Transl. Med. 13, 160 (2015).
Cox, E. M., Edmund, A. V., Kratz, E., Lockwood, S. H. & Shankar, A. Regulatory affairs 101: introduction to expedited regulatory pathways. Clin. Transl. Sci. 13, 451–461 (2020).
Kulkarni, T. N. & Kulkarni, N. G. Authoring a periodic adverse drug experience report…here’s what you need to know! Perspect. Clin. Res. 10, 95–99 (2019).
Alapati, D., Egan, P. & Holcombe, J. Understanding conflict of interest for academic entrepreneurs. In Academic Entrepreneurship for Medical and Health Scientists. PubPub Edition (2021).
Collins, L. R. & Shepard, K. A. CIRM tools and technologies: breaking bottlenecks to the development of stem cell therapies. Stem Cell Transl. Med. 9, 1129–1136 (2020).
Yuh, D. D. Value analysis committees: not just another committee to get out of. J. Thorac. Cardiovasc. Surg. 155, 686–687 (2018).
Dang, A. & Kaur, K. Comparative effectiveness research and its utility in in-clinic practice. Perspect. Clin. Res. 7, 9–14 (2016).
Westrich, K. D., Wilhelm, J. A. & Schur, C. L. Comparative effectiveness research in the USA: when will there be an impact on healthcare decision-making? J. Comp. Eff. Res. 5, 207–216 (2016).
Carter, R. G. et al. Innovation, entrepreneurship, promotion, and tenure. Science 373, 1312–1314 (2021).
Caulfield, T., Harmon, S. H. & Joly, Y. Open science versus commercialization: a modern research conflict? Genome Med. 4, 17 (2012).
Tompkins, B. A. et al. IMPACT: Preclinical studies of cell therapy for human disease. Circ. Res. 122, 1006–1020 (2018).
Ginty, P., Singh, P., Smith, D., Hourd, P. & Williams, D. Achieving reimbursement for regenerative medicine products in the USA. Regen. Med. 5, 463–469 (2010).
Bubela, T. et al. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regen. Med. 10, 897–911 (2015).
Marks, L. V. Collaboration — a competitor’s tool: the story of Centocor, an entrepreneurial biotechnology company. Bus. History 51, 529–546 (2009).
Cheever, M. A. & Higano, C. S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520–3526 (2011).
Schmidt, C. Gintuit cell therapy approval signals shift at US regulator. Nat. Biotechnol. 30, 479–479 (2012).
Schmidt, C. FDA approves first cell therapy for wrinkle-free visage. Nat. Biotechnol. 29, 674–675 (2011).
Boss, W. K. et al. Autologous cultured fibroblasts as cellular therapy in plastic surgery. Clin. Plastic Surg. 27, 613–626 (2000).
Morrison, C. Boom: 2018’s biotech IPOs. Nat. Rev. Drug Discov. 18, 3–6 (2019).
Markert, M. L. et al. Successful formation of a chimeric human thymus allograft following transplantation of cultured postnatal human thymus. J. Immunol. 158, 998–1005 (1997).
Markert, M. L. et al. Transplantation of thymus tissue in complete DiGeorge syndrome. N. Engl. J. Med. 341, 1180–1189 (1999).
Markert, M. L. et al. Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. Blood 102, 1121–1130 (2003).
Markert, M. Parathyroid and thymus transplantation in DiGeorge syndrome subjects. US patent 0041854 A1 (2009).
Markert, M. L. Parathyroid and thymus transplantation in DiGeorge syndrome subjects. World patent application WO 107601 A3 (2006).
Markert, M. L. Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants. World patent application WO 165197 A1 (2019).
Markert, M. L. et al. Methods of determining the suitability of cultured thymus tissue for implantation into humans and associated methods of use. Canadian patent application 3150732 A1 (2021).
Allen-Hoffmann, B. L. et al. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J. Investig. Dermatol. 114, 444–455 (2000).
Schurr, M. J. et al. Phase I/II clinical evaluation of stratagraft: a consistent, pathogen-free human skin substitute. J. Trauma. Acute Care Surg. 66, 866 (2009).
US National Library of Medicine. StrataGraft™ skin tissue (human donor skin) in the surgical management of complex skin defects. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00618839 (2019).
Centanni, J. M. et al. StrataGraft Skin substitute is well-tolerated and is not acutely immunogenic in patients with traumatic wounds: results from a prospective, randomized, controlled dose escalation trial. Ann. Surg. 253, 672 (2011).
US National Library of Medicine. StrataGraft® skin tissue as an alternative to autografting deep partial-thickness burns. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01437852 (2019).
US National Library of Medicine. StrataGraft® skin tissue as an alternative to autografting full-thickness complex skin defects. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03005054 (2016).
Gibson, A. L. F. et al. A phase 3, open-label, controlled, randomized, multicenter trial evaluating the efficacy and safety of StrataGraft® construct in patients with deep partial-thickness thermal burns. Burns 47, 1024–1037 (2021).
US National Library of Medicine. StrataGraft skin tissue expanded access at specific study sites (StrataCAT). ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04123548 (2021).
US National Library of Medicine. Scarring in stratagraft-treated vs. autograft-treated burn wounds: a clinical and histological investigation. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04896346 (2022).
US National Library of Medicine. StrataGraft safety, tolerability and efficacy in pediatric subjects (StrataSTEPS). ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05517902 (2023).
US National Library of Medicine. StrataGraft overlay of meshed autograft in full-thickness thermal Burns (StrataSOMA). ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04765202 (2023).
Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849–860 (2017).
Walsh, C. E. & Batt, K. M. Hemophilia clinical gene therapy: brief review. Transl. Res. 161, 307–312 (2013).
US National Library of Medicine. Gene transfer clinical trial for spinal muscular atrophy type 1. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02122952 (2022).
Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722 (2017).
US National Library of Medicine. Study evaluating the safety and pharmacokinetics of JCAR017 in B-cell non-Hodgkin lymphoma (TRANSCEND-NHL-001). ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02631044 (2023).
Anderson, D. E., Gridley, A. & Crawford, D. C. Next generation cartilage repair and the pre-arthroplasty patient. Oper. Tech. Sports Med. 30, 150956 (2022).
|
Sources 2/ https://www.nature.com/articles/s44222-023-00095-9 The mention sources can contact us to remove/changing this article |
What Are The Main Benefits Of Comparing Car Insurance Quotes Online
LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos
to request, modification Contact us at Here or [email protected]
 |
 |
 |
